Novo Nordisk
NYSE:NVOPharmaBagsværd, Denmark, Denmark · Est. 1923 · 48,500 employees
Novo Nordisk is a global healthcare company specializing in diabetes care, obesity management, and other chronic diseases with a focus on insulin and GLP-1 receptor agonists.
35
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
43
Indications↗
Distinct diseases across all programs
1,280
Clinical Trials↗
All sponsored trials (all statuses)
75
Orange Book Patents
Across 4 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
35 drugs in development
Approved1
Phase 310
Phase 212
Phase 119
Preclinical9
By Therapeutic Area
top 6
Metabolic & Endocrine
2139%
Gastroenterology
713%
Cardiovascular
59%
Hematology
59%
Nephrology
36%
Rare Disease
24%
R&D Momentum
90/100
Pipeline Velocity
73/100
Trial Completion Rate
95/100
Pipeline Concentration
22/100
Pipeline Freshness
81/100
Strategic Signals
- ↗Active in Neurology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Jul 14, 2026
Recruiting
Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Obstructive Sleep Apnoea Treated With Positive Airway Pressure (AMAZE 4)
Jul 14, 2026
Recruiting
Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure (AMAZE 3)
Jul 11, 2026
Recruiting
Evaluation of Different Dose Escalation Regimens for NNC0662-0419 in Participants With Obesity
Jul 10, 2026
Recruiting
Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
Jul 10, 2026
Withdrawn
A Placebo-controlled Comparability Study to Compare Two Presentations of CagriSema in Participants With Overweight or Obesity
Jul 10, 2026
Active, not recruiting
Investigation of Pharmacokinetics of Two Different Presentations of Cagrilintide in Participants With Overweight and Obesity
Jul 10, 2026
Recruiting
Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Type 2 Diabetes (AMAZE 2)
Jul 10, 2026
Active, not recruiting
A Study Evaluating the Safety and Efficacy of Once-weekly Dosing of Somapacitan in a Basket Study Design in Paediatric Participants With Short Stature Either Born Small for Gestational Age or With Turner Syndrome, Noonan Syndrome or Idiopathic Short Stature
Jul 10, 2026
Active, not recruiting
Effect and Safety of Liraglutide 3.0 mg on Weight Management in Children With Obesity Aged 6 to Below 12 Years: 56-week, Double-blind, Randomised, Placebo-controlled Trial
Jul 10, 2026
Recruiting
Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Knee Osteoarthritis (AMAZE 5)
Jul 10, 2026
Withdrawn
A Phase 2 Study to Compare Two Presentations of CagriSema in Participants With Type 2 Diabetes
Jul 10, 2026
Recruiting
Efficacy and Safety of NNC0487-0111 s.c. Once Weekly in Participants With Obesity Who Have Reached Target Dose During run-in Period (AMAZE 12)
Details
Company Info
Company Overview
$550.0B
Mkt Cap
$21.4B
Revenue
—
Cash
CEOLars Fruergaard Jørgensen
Founded1923
Employees48,500
HQBagsværd, Denmark, Denmark
ExchangeNYSE:NVO
Websitenovonordisk.com
LinkedInCompany Page
Therapeutic Focus
CardiovascularMetabolic & EndocrinePsychiatryNeurologyNephrologyMusculoskeletalOtherInfectious DiseaseOncologyGastroenterologyRespiratoryOphthalmologyImmunologyRare DiseaseHematologyDermatology
Pipeline
Drug Pipeline
Therapeutic Area
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Cardiovascular(5 drugs)
—
1
2
3
—
Cardiovascular(5 drugs)
Gastroenterology(7 drugs)
—
3
4
—
—
Gastroenterology(7 drugs)
Hematology(5 drugs)
—
3
1
1
—
Hematology(5 drugs)
Metabolic & Endocrine(21 drugs)
6
10
5
6
1
Metabolic & Endocrine(21 drugs)
Nephrology(3 drugs)
—
1
2
—
—
Nephrology(3 drugs)
Neurology(1 drug)
—
—
1
—
—
Neurology(1 drug)
Oncology(1 drug)
—
—
1
—
—
Oncology(1 drug)
Rare Disease(2 drugs)
1
—
—
1
—
Rare Disease(2 drugs)
Unknown / Other(9 drugs)
5
2
1
2
—
Unknown / Other(9 drugs)
Regulatory
Regulatory Timeline
20043 events
FDAAug 20
Estrace — FEMTRACE
Application NDA021633 (NDA)
FDAJun 8
Estrace — MENOSTAR
Application NDA021674 (NDA)
FDAFeb 9
Estrace — ESTROGEL
Application NDA021166 (NDA)
20051 event
FDAJun 16
LEVEMIR — LEVEMIR
Application BLA021536 (BLA)
20061 event
FDADec 15
Estrace — ELESTRIN
Application NDA021813 (NDA)
20072 events
FDAJul 27
Estrace — EVAMIST
Application NDA022014 (NDA)
FDAJun 4
Estrace — DIVIGEL
Application NDA022038 (NDA)
20091 event
FDANov 25
Estrace — VAGIFEM
Application NDA020908 (NDA)
20101 event
FDAJan 25
Victoza — VICTOZA
Application NDA022341 (NDA)
20142 events
FDADec 23
Victoza — SAXENDA
Application NDA206321 (NDA)
FDASep 23
Estrace — MINIVELLE
Application NDA203752 (NDA)
20151 event
FDASep 25
TRESIBA — TRESIBA
Application BLA203314 (BLA)
20172 events
FDADec 5
Ozempic — OZEMPIC
Application NDA209637 (NDA)
FDASep 29
FIASP — FIASP
Application BLA208751 (BLA)
20181 event
FDAMay 29
Estrace — IMVEXXY
Application NDA208564 (NDA)
20211 event
FDAJun 4
Ozempic — WEGOVY
Application NDA215256 (NDA)
20231 event
FDASep 29
Rivfloza — RIVFLOZA
Application NDA215842 (NDA)
20242 events
FDADec 20
ALHEMO — ALHEMO
Application BLA761315 (BLA)
FDADec 9
Ozempic — RYBELSUS
Application NDA213051 (NDA)
20251 event
FDADec 22
Ozempic — WEGOVY
Application NDA218316 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)